StockData
Invivyd, Inc. logo

Invivyd, Inc. (IVVD) company profile

IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3048% below fair value
$0.51−0.03 (-4.67%)

Close on Nov 17, 2026Market cap $151.09MP/E –Yield –

About Invivyd

Biological Products, (No Diagnostic Substances), SIC 2836

Invivyd, Inc. is a biopharmaceutical company that discovers, develops, and commercializes monoclonal antibody therapies to prevent and treat serious viral infectious diseases. Its primary product is PEMGARDA, an authorized monoclonal antibody used as pre-exposure prophylaxis against COVID-19. The company also develops investigational candidates, including VYD2311 for COVID-19 and VBY329 for respiratory syncytial virus, alongside early research targeting measles. Its treatments serve vulnerable populations, specifically immunocompromised adults and adolescents who cannot generate an adequate immune response from vaccination, distributed through specialized healthcare practitioners in oncology, hematology, rheumatology, and transplantation.

The company conducts commercial activities and maintains a field sales force in the United States. Its clinical evaluations include trials conducted in Australia, alongside global studies for foundational antibody programs. Invivyd operates dedicated laboratory space and relies on external contract research organizations as well as WuXi Biologics in Hong Kong for development, manufacturing, and product supply. The provided text does not state the location of the company's headquarters.

Summary of the business section of Invivyd's latest annual report, written by StockData.

Company profile

Company

Legal name
Invivyd, Inc.
Headquarters
New Haven, CT
Address
205 Church Street
Phone
(781) 819-0080
Employees
122, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
IVVD
Former tickers
ADGI until Sep 13, 2022
Exchange
Nasdaq
IPO date
Aug 6, 2021
Shares outstanding
295M, Jul 30, 2026
Public float
$50.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1832038
CUSIP
00534A102
ISIN
US00534A1025
FIGI
BBG00W4ML039
Share class FIGI
BBG00W4ML048
EIN
85-1403134

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Marc EliaChief Executive Officer, Director9,248,250
William E. DukeChief Financial Officer168,937
Robert D. Allen IIIChief Scientific Officer178,765
Jill AndersenChief Legal Officer, Secretary284,274
Timothy Edward LeeChief Commercial Officer178,937
Julie GreenChief Human Resources Officer168,937
Michael MinaCMO and Chief Epidemiologist–
Ian SheffieldDirector–
Terrance McGuireDirector3,066,757
Kevin F. McLaughlinDirector50,000
Paul BolnoDirector–
Ajay RoyanDirector11,241,580
Tamsin BerryDirector–
Christine LindenboomDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
William Duke, Jr.
Chief Financial Officer
$485.00K$256.08K$483.00K$905.45K$11.70K$2.14M+237%
Jill Andersen
Chief Legal Officer
$500.00K$264.00K$805.00K$905.45K$11.71K$2.49M–
Timothy Lee
Chief Commercial Officer
$455.00K$240.24K$483.00K$905.45K$11.63K$2.10M+106%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 6, 2021
Offer price
$17.00
Securities offered
18,200,000
Gross proceeds
$309.40M
Exchange
Nasdaq
First trading day
Aug 6, 2021
First-day close
$20.88+22.8%
Lock-up ends (est.)
Feb 2, 2022

“The initial public offering price of our common stock is $17.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 1, 2026, we had 122 employees, all of which were full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?